With the aim of strengthening its pipeline of drugs targeting cancer, inflammation and other conditions, Inspyr Therapeutics has agreed to acquire Lewis and Clark Pharmaceuticals.
Following the all-stock transaction, the target company’s shareholders will own 50% of the acquirer company’s common shares.
Go deeper with GlobalData
The acquirer company is a clinical-stage biotechnology company, whereas the target company is a biotechnology company.
Both companies involved in the transaction are based in the US.
Nippon Suisan Kaisha’s subsidiary Nissui Pharmaceutical has reached an agreement to its pharmaceutical subsidiary company based in Yamanashi, Japan, to Senshukai.
Also based in Japan, the acquirer company is engaged in mail-order business.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
